Recursion Pharmaceuticals is using robots to find treatments for rare diseases like sickle cell anemia and cystic fibrosis. » Read More
By: Justina Crabtree
While the development of contraceptives aimed at men is gaining ground, interest from big pharma just isn't there, according to one expert. » Read More
Dermatologists and other specialists are three times more likely than primary care providers to prescribe brand name versions of drugs known as topical immunomodulators. » Read More
CNBC's Meg Tirrell speaks with John Cox, Bioverativ CEO, about the company's spinoff from Biogen, its new innovations in treating hemophilia.
By 2030, 70 percent of HIV patients will be over 50. Now success of HIV drugs poses a new challenge: treating it as a geriatric condition.
Nadav Kidron, CEO of Oramed Pharmaceuticals, talks about the company's latest offering and the issue of drug pricing.
The drug was found to be generally well-tolerated with no serious adverse events or discontinuations reported, the company said.
Marathon says it will charge $89,000 for its Duchenne muscular dystrophy treatment, despite it having sold elsewhere for just $1,000.
Allergan said it would buy Zeltiq Aesthetics for about $2.48 billion to gain access to its flagship body contouring technology.
Marathon said the muscular dystrophy drug will cost $89,000 a year, but that the company will provide a "robust" assistance program for uninsured patients.
Discussing the potential downside to pharmaceutical companies developing cures with Dr. Peter Bach, Memorial Sloan Kettering Center for Health Policy, and Brian Skorney, Baird biotechnology analyst. CNBC's Meg Tirrell also weighs in.
The pharma bro Shkreli previously won permission to speak at two other universities, but neither event happened because of protests.
David Gortler, associate professor at Georgetown University, says it is good that people are having conversations on the FDA but drug pricing remains complicated.
The "Fast Money" traders discuss the trade on Gilead, which is down about 9 percent.
A new SEC filing shows that Shkreli is involved in a tech start-up whose executives include a long-time Shkreli associate.
Sources said there is a significant gap over the company's valuation between Tesaro and potential acquirers.
Shares of Gilead Sciences are in the red after the drugmaker issued a weak sales forecast for its hepatitis C drugs.
Gilead said it predicts 2017 hepatitis C drug sales of $7.5 billion to $9 billion, lower than the $12 billion Wall Street had expected.
See which stocks are making moves after the bell on Tuesday.
Get the best of CNBC in your inbox